---

Dapagliflozin: A molecule for type-2 diabetes mellitus

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Ravinandan A P*, Hunsur Nagendra Vishwas, Shashank S Hosur, Mohammed Mustafa G. , Kavya H.B.

Volume : 9, Issue : 4, Year : 2022

Article Page : 156-162

https://doi.org/10.18231/j.ijpca.2022.029

Suggest article by email

Get Permission

Abstract

Dapagliflozin which is also known as Farxiga in the US and Forxiga in the EU is a drug which was developed by Bristol-Myers Squibb in partnership with Astra Zeneca. It is also available in Oxra and it is marking by Sun Pharmaceutical Industries Ltd. It contains the active substance Dapagliflozin which is the second member of selective sodium glucose co-transporter-2 (SGLT-2) inhibitor and it is the first group among oral anti-diabetic agents which are independent of insulin secretion. The drug Dapagliflozin shows the action of reducing the blood glucose by preventing the reabsorption of glucose at the renal proximal tubule and avoids insulin resistance. It is a new molecule that helps in maintaining the glycemic control either in mono therapy or combinational therapy or add on therapy. This is a review article which summarizes the details of Dapagliflozin.

Keywords: Type2 Diabetes Mellitus, Dapagliflozin, Selective Sodium Glucose Co, Transporter2 (SGLT2) Inhibitor

How to cite : Ravinandan A P, Vishwas H N, Hosur S S , Mohammed Mustafa G., H.b. K, Dapagliflozin: A molecule for type-2 diabetes mellitus. Int J Pharm Chem Anal 2022;9(4):156-162

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.